A Phase 3 interventional study of insulin degludec/liraglutide and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 302 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-19.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 8 that started in 2011, is one of 49 in phase 3, and was the 20th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,663 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 27 open now, 31 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 16th largest by enrollment of the 430 interventional ones that give a count, is one of 23 that started in 2011, is one of 187 in phase 3, and was the 213th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 645 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin degludec (IDeg) and liraglutide (Lira) in subjects with type 2 diabetes. Subjects are to continue their pre-trial treatment with metformin or metformin + pioglitazone throughout the entire trial.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 1,663 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec
Drug: insulin degludec/liraglutide
Drug: liraglutide
Drug pages: Insulin degludecStudies of Insulin degludecInsulin degludec pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LiraglutideStudies of LiraglutideLiraglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.
Values of mean change in HbA1c.
Time frame: Week 0, week 26
Mean Change From Baseline in Body Weight at Week 26
Values of mean change in body weight.
Time frame: Week 0, Week 26
Number of Hypoglycaemic Episodes
Reported hypoglycemaic episodes are number of hypoglycemic events per 100 patient years of exposure.
Time frame: Weeks 0-26
Change From Baseline in Incremental Area Under the Curve 0-4h (iAUC0-4h) Derived From the Glucose Concentration Profile During Meal Test
Values of mean change in normalised iAUC0-4h values based on LOCF data derived from the glucose concentration profiles during a meal test. The meal test was performed at selected sites at baseline and after 26 weeks of treatment in the main trial period. The incremental AUC was calculated using the trapezoidal method and the resulting area was divided length of the observation period to yield the (normalised) prandial increment in mmol/L using the available valid glucose observations and the associated actual elapsed time point.
Time frame: Week 0, Week 26
Mean Actual Daily Insulin Dose
Mean of the actual doses recorded at visit 28 (Week 26).
Time frame: Week 26
Countries: 19; Sites: 271; Number of sites as in parenthesis. Australia (7), Canada (14 ), Finland (5 ), Germany (12 ), Hungary (6), India (23), Ireland (2), Italy (6), Malaysia (5), Mexico (2 ), Russian Federation (11), Singapore (3), Slovakia (5), South Africa (13), Spain (8), Taiwan (3), Thailand (4), United Kingdom (16) and United States (126).
| Milestone | IDeg | IDegLira | Liraglutide |
|---|---|---|---|
| Started | 414 | 834 | 415 |
| Exposed | 413 | 826 | 413 |
| Completed | 366 | 736 | 342 |
| Not completed | 48 | 98 | 73 |
| Withdrew: Adverse event | 8 | 10 | 24 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 2 | 0 |
| Withdrew: Withdrawal criteria | 34 | 69 | 40 |
| Withdrew: Unclassified | 5 | 16 | 9 |
| Milestone | IDeg | IDegLira | Liraglutide |
|---|---|---|---|
| Started | 333 | 665 | 313 |
| Completed | 305 | 621 | 285 |
| Not completed | 28 | 44 | 28 |
| Withdrew: Adverse event | 1 | 5 | 2 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Withdrawal criteria | 14 | 19 | 16 |
| Withdrew: Unclassified | 13 | 18 | 9 |
Values of mean change in HbA1c.
| Percentage of glycosylated haemoglobin | IDeg | IDegLira | Liraglutide |
|---|---|---|---|
| Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. | -1.44 ± 1.03 | -1.91 ± 1.07 | -1.28 ± 1.13 |
Values of mean change in body weight.
| kg | IDeg | IDegLira | Liraglutide |
|---|---|---|---|
| Mean Change From Baseline in Body Weight at Week 26 | 1.6 ± 4.0 | -0.5 ± 3.5 | -3.0 ± 3.5 |
Reported hypoglycemaic episodes are number of hypoglycemic events per 100 patient years of exposure.
| Events per 100 patient years of exposure | IDeg | IDegLira | Liraglutide |
|---|---|---|---|
| Number of Hypoglycaemic Episodes | 256.7 | 180.2 | 22.0 |
Values of mean change in normalised iAUC0-4h values based on LOCF data derived from the glucose concentration profiles during a meal test. The meal test was performed at selected sites at baseline and after 26 weeks of treatment in the main trial period. The incremental AUC was calculated using the trapezoidal method and the resulting area was divided length of the observation period to yield the (normalised) prandial increment in mmol/L using the available valid glucose observations and the associated actual elapsed time point.
| mmol/L | IDeg | IDegLira | Liraglutide |
|---|---|---|---|
| Change From Baseline in Incremental Area Under the Curve 0-4h (iAUC0-4h) Derived From the Glucose Concentration Profile During Meal Test | -0.17 ± 1.98 | -0.87 ± 1.65 | -0.78 ± 1.62 |
Mean of the actual doses recorded at visit 28 (Week 26).
| units | IDeg | IDegLira |
|---|---|---|
| Mean Actual Daily Insulin Dose | 53 ± 28 | 38 ± 13 |
Collected over Adverse events (AEs) were collected from first day of exposure to randomised treatment of 52 weeks (26 week main period + 26 week extension period) + 7 days follow-up after the last day on randomised treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg | — | 22/412 (5.3%) | 160/412 (38.8%) |
| IDegLira | — | 38/825 (4.6%) | 386/825 (46.8%) |
| Liraglutide | — | 24/412 (5.8%) | 241/412 (58.5%) |
| Event | IDeg | IDegLira | Liraglutide |
|---|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/412 | 1/825 | 3/412 |
| Angina pectorisCardiac disorders | 0/412 | 2/825 | 2/412 |
| Angina unstableCardiac disorders | 2/412 | 0/825 | 0/412 |
| Umbilical herniaGastrointestinal disorders | 0/412 | 0/825 | 2/412 |
| CholelithiasisHepatobiliary disorders | 2/412 | 0/825 | 1/412 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 2/412 | 0/825 | 0/412 |
| Acute coronary syndromeCardiac disorders | 1/412 | 0/825 | 0/412 |
| Acute myocardial infarctionCardiac disorders | 1/412 | 2/825 | 1/412 |
| Atrial fibrillationCardiac disorders | 0/412 | 1/825 | 1/412 |
| GoitreEndocrine disorders | 0/412 | 0/825 | 1/412 |
| Event | IDeg | IDegLira | Liraglutide |
|---|---|---|---|
| NauseaGastrointestinal disorders | 16/412 | 85/825 | 92/412 |
| DiarrhoeaGastrointestinal disorders | 28/412 | 84/825 | 67/412 |
| HeadacheNervous system disorders | 45/412 | 106/825 | 60/412 |
| NasopharyngitisInfections and infestations | 52/412 | 115/825 | 55/412 |
| VomitingGastrointestinal disorders | 10/412 | 41/825 | 37/412 |
| Lipase increasedInvestigations | 18/412 | 48/825 | 35/412 |
| Upper respiratory tract infectionInfections and infestations | 34/412 | 64/825 | 33/412 |
| Decreased appetiteMetabolism and nutrition disorders | 2/412 | 22/825 | 30/412 |
| Back painMusculoskeletal and connective tissue disorders | 20/412 | 45/825 | 23/412 |
| DyspepsiaGastrointestinal disorders | 5/412 | 28/825 | 22/412 |
The full analysis set (FAS) included all randomised subjects and missing data was imputed using last observation carried forward (LOCF). Three subjects did not have their case book signed off due to discontinuation of an investigator's participation in the trial, hence 1 subject in each arm was excluded from the FAS.
| Age, Continuous(years) | IDeg | IDegLira | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 54.9 ± 9.7 | 55.1 ± 9.9 | 55.0 ± 10.2 | 55.0 ± 9.9 |
| Sex: Female, Male(Participants) | IDeg | IDegLira | Liraglutide | Total |
|---|---|---|---|---|
| Female | 213 | 398 | 206 | 817 |
| Male | 200 | 435 | 208 | 843 |
| Body Weight(kg) | IDeg | IDegLira | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 87.4 ± 19.2 | 87.2 ± 19.0 | 87.4 ± 18.0 | 87.3 ± 18.8 |
| Normalised Incremental Area under curve (AUC)(mmol/L) | IDeg | IDegLira | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 4.12 ± 1.80 | 4.11 ± 2.05 | 4.12 ± 1.82 | 4.11 ± 1.93 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDeg | IDegLira | Liraglutide | Total |
|---|---|---|---|---|
| Mean | 8.3 ± 1.0 | 8.3 ± 0.9 | 8.3 ± 0.9 | 8.3 ± 0.9 |
Showing the first 100 of 302 sites across 20 countries. Choose a country and city above to see the rest.
Ran from May 2011 to primary completion in May 2012, 12 months.
Results were first posted in Jun 2017, 5 years after primary completion. A results delay was requested in Dec 2012.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 12 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide